Adma Biologics (ADMA) Non-Current Assets (2011 - 2025)

Adma Biologics has reported Non-Current Assets for 14 years, with the latest figure at $157.7 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets changed 0.29% year-over-year to $157.7 million; the trailing twelve-month figure through Dec 2025 stood at $641.3 million (up 70.18% YoY), and the FY2025 full-year result was $157.7 million, changed 0.29% from the prior year.
• Non-Current Assets for Q4 2025 stood at $157.7 million, down from $166.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $166.0 million in Q3 2025, with the low at $58.4 million in Q1 2021.
• Historically, Non-Current Assets has averaged $93.4 million across 5 years, with a median of $74.9 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets slipped 7.55% — and 2025, when it surged 129.25%.
• Adma Biologics' Non-Current Assets stood at $67.5 million in 2021, then rose by 15.6% to $78.1 million in 2022, then decreased by 7.55% to $72.2 million in 2023, then jumped by 117.92% to $157.3 million in 2024, then gained by 0.29% to $157.7 million in 2025.
• The last three Non-Current Assets figures came in at $157.7 million (Q4 2025), $166.0 million (Q3 2025), and $158.8 million (Q2 2025), per Business Quant data.